The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth
Abstract
BACKGROUND: Preterm birth is the major complication of pregnancy associated with perinatal mortality and morbidity and occurs in up to 6% to 10% of all births. Administration of progesterone for the prevention of preterm labour has been advocated. OBJECTIVES: To assess the benefits and harms of progesterone administration during pregnancy in the prevention of preterm birth. SEARCH STRATEGY: We searched the Cochrane Pregnancy and Childbirth Group's Specialised Register of Controlled Trials (March 2005), the Cochrane Central Register of Controlled Trials (The Cochrane Library, Issue 3, 2004), MEDLINE (1965 to January 2005), EMBASE (1988 to August 2004), and Current Contents (1997 to August 2004). SELECTION CRITERIA: All published and unpublished randomised controlled trials, in which progesterone was given by any route for preventing preterm birth. DATA COLLECTION AND ANALYSIS: Standard methods of the Cochrane Collaboration and the Cochrane Pregnancy and Childbirth Group were used. Evaluation of methodological quality and trial data extraction were undertaken independently by two authors. Results are presented using relative risk with 95% confidence intervals. MAIN RESULTS: For all women administered progesterone, there was a reduction in the risk of preterm birth less than 37 weeks (six studies, 988 participants, relative risk (RR) 0.65, 95% confidence interval (CI) 0.54 to 0.79) and preterm birth less than 34 weeks (one study, 142 participants, RR 0.15, 95% CI 0.04 to 0.64). Infants born to mothers administered progesterone were less likely to have birthweight less than 2500 grams (four studies, 763 infants, RR 0.63, 95% CI 0.49 to 0.81) or intraventricular haemorrhage (one study, 458 infants, RR 0.25, 95% CI 0.08 to 0.82). There was no difference in perinatal death between women administered progesterone and those administered placebo (five studies, 921 participants, RR 0.66, 95% CI 0.37 to 1.19). There were no other differences reported for maternal or neonatal outcomes. AUTHORS' CONCLUSIONS: Intramuscular progesterone is associated with a reduction in the risk of preterm birth less than 37 weeks' gestation, and infant birthweight less than 2500 grams. However, other important maternal and infant outcomes have been poorly reported to date, with most outcomes reported from a single trial only (Meis 2003). It is unclear if the prolongation of gestation translates into improved maternal and longer-term infant health outcomes. Similarly, information regarding the potential harms of progesterone therapy to prevent preterm birth is limited. Further information is required about the use of vaginal progesterone in the prevention of preterm birth.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of recurrent preterm delivery by 17 alpha–hydroxyprogesterone caproate
Meis, P. J., Klebanoff, M., Thom, E., Dombrowski, M. P., Sibai, B., Moawad, A. H., Spong, C. Y., Hauth, J. C., Miodovnik, M., Varner, M. W., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035140 · Cited by 1,555
Goldenberg, R. L., & Rouse, D. J. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390506 · Cited by 758
Mercer, B. M., Goldenberg, R. L., Moawad, A. H., Meis, P. J., Iams, J. D., Das, A. F., Caritis, S. N., Miodovnik, M., Menard, M. K., Thurnau, G. R., et al. (1999) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(99)70111-0 · Cited by 520
Inhibition of oxytocin receptor function by direct binding of progesterone
Grazzini, E., Guillon, G., Mouillac, B., & Zingg, H. H. (1998) · Nature · doi:10.1038/33176 · Cited by 466
Condon, J. C., Jeyasuria, P., Faust, J. M., Wilson, J. W., & Mendelson, C. R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1633616100 · Cited by 270
Cited by
Progesterone and the Risk of Preterm Birth among Women with a Short Cervix
Fonseca, E. B., Celik, E., Parra, M., Singh, M., & Nicolaides, K. H. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067815 · Cited by 1,086
Chang, H. H., Larson, J., Blencowe, H., Spong, C. Y., Howson, C. P., Cairns-Smith, S., Lackritz, E. M., Lee, S. K., Mason, E., Serazin, A. C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61856-x · Cited by 556
Iams, J. D., Romero, R., Culhane, J. F., & Goldenberg, R. L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60108-7 · Cited by 500
Progesterone and preterm birth prevention: translating clinical trials data into clinical practice
(2012) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2012.03.010 · Cited by 341
Dodd, J. M., Jones, L., Flenady, V., Cincotta, R., & Crowther, C. A. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004947.pub3 · Cited by 331
Self-citation
Metadata
- Authors
- Dodd, J. M., Flenady, V., Cincotta, R., & Crowther, C. A.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2006-01-25
- Issue
- 1
- Pages
- CD004947-CD004947
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W1495790695
- Cited by
- 232
- References
- 5
- Type
- reference entry
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. https://app.cochat.ai/papers/10.1002/14651858.cd004947.pub2
- The paper
- Dodd, J. M., Flenady, V., Cincotta, R., & Crowther, C. A. (2006). Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd004947.pub2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.